Novavax shared positive initial results from the Phase I/II clinical study of the company’s proposed combination vaccine for COVID-19.
France is facing its worst bird flu crisis in history as a rare rebound in outbreaks of the highly contagious virus reached the country’s largest poultry producing regions with cullings topping more than 12 million birds.
HIV drugs may lower COVID risk; COVID and flu co-infection raises risk of severe illness, deathClinical Trials, Coronavirus Disease (COVID-19) Pandemic, HIV, Hospitalized COVID-19 Patients, Influenza, Nasal Sprays, Protease inhibitors, R&D, SARS-CoV-2 virus, Small Molecules, The Lancet, Therapeutics
Certain drugs used to treat HIV may have a role in preventing SARS-CoV-2 infections, according to preliminary data that may help explain why people living with the condition have not appeared to be at higher risk for serious COVID-19 despite being generally more vulnerable to infections. Additionally, having COVID-19 and influenza at the same time puts hospitalized adults at much greater risk of critical illness and death compared to having COVID-19 without the flu, researchers reported in The Lancet.
Moderna Announces Triple Threat Booster Against VirusesBusiness, CDC, Clinical Trials, COVID-19 Vaccinations, Endemic, Hospitalized COVID-19 Patients, Immunogenicity, Influenza, Messenger RNA (mRNA) Vaccines, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), R&D, Respiratory Syncytial Virus (RSV) Infection, SARS-CoV-2 virus, Vaccines, Viruses
Moderna is broadening the company’s vaccine horizons once again using mRNA technology, widely known for its use in COVID-19 vaccinations. Moderna announced two new vaccine development programs targeting a variety of viruses.
Moderna Inc. has begun a late-stage study of a vaccine for respiratory syncytial virus (RSV) based on the same technology used to develop the company’s COVID-19 shots.
Money on the Move: January 19 – 25Algorithms, Appointments, Biotech, Business, Cell Therapy, Cells, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Coronavirus, CRISPR, Drug Discovery, Fibrosis, Financing, Gene Editing, Inflammatory Bowel Disease (IBD), Influenza, Mammalian, Moderna, Monoclonal Antibodies, Nasal drug delivery, Oncology, People on the Move, Product Pipelines, R&D, RNA, Series A, Series B
Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.
The Omicron variant of COVID-19 is on track to infect more than half of Europeans, but it should not yet be seen as a flu-like endemic illness, the World Health Organization (WHO) said on Tuesday.
A new study shows that there might be a way to protect against influenza infection without needing to stir up antibody response.
Scientists are scrambling to find the cause for the sudden spike in human cases of avian influenza A (H5N6) in China to 21 during year-to-date 2021, from only five in 2020, reports say.
The U.S. Food and Drug Administration approved Seqirus’ Flucelvax Quadrivalent (Influenza Vaccine), the company’s cell-based quadrivalent influenza vaccine, for an expanded age indication for children as young as 6 months old.